SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Hypertension is the leading modifiable cause of premature death and hence one of the
global targets of World Health Organization for prevention. Hypertension also affects the …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

OBJECTIVE These post hoc analyses of the Semaglutide Treatment Effect in People with
obesity (STEP) 1–3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the …

In modern cardiology, sodium‐glucose cotransporter 2 (SGLT2) inhibitors are critical
components of heart failure (HF) treatment algorithms and exert their effects primarily by …

Obesity is a serious chronic disease and an independent risk factor for the new onset and
progression of chronic kidney disease (CKD). CKD prevalence is expected to increase, at …

The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiovascular and
renal outcomes has not been systematically reviewed across baseline kidney function …

In diabetic kidney disease (DKD), the long-term hyperactivation of yes-associated protein
(YAP)/transcriptional coactivator PDZ-binding motif (TAZ) in renal proximal tubule epithelial …